A Full Lineup at RESI Boston

11 Aug

By Rory McCann, Director of Marketing & Conference Producer, LSN

RESI Boston returns September 21-23, along with the Innovator’s Pitch Challenge (IPC) which is now full! Applications for the IPC are closed early due to the immense volume of interest. The IPC is a pitch competition designed for early-stage companies to pitch directly to a panel of investors who are a fit for their product and stage of development, specifically in the life science and healthcare spaces. The IPC has established itself as a unique opportunity for participating startups to increase their visibility, and is finally returning after more than two years of virtual pitching. Life Science Nation is proud of the number and quality of applicants and look forward to announcing the full list of 50+ finalists ahead of RESI Boston.

While pitch applications are closed, RESI Boston registration is not! Partnering opens later this month, which includes complimentary tutorials on how to use the partnering system, with detailed examples and Q&A. Register for RESI Boston in time to start booking meetings with investors based on fit and sign up to join a tutorial explaining the strengths of the platform and how to make it work for you. Still interested in pitching? Contact us to learn about upcoming pitch events at RESI!

RESI-Boston-2022-Banner - new - 1100px

Learn to Leverage IP for Growth at RESI Boston

11 Aug

By Antoinette Lowre, Manager of Business Development, LSN

Husch Blackwell is coming to RESI Boston! Join us September 21 for the Leveraging IP for Growing an Investable MedTech Company panel, hosted by Husch Blackwell, and featuring industry leaders sharing their experiences in order to help other early-stage entrepreneurs. Husch Blackwell is a law firm focused on delivering in-depth solutions to the most complex business challenges. They bring together the best legal minds and reach beyond law to include experienced industry professionals providing a greater perspective to their clients.

The panel is for industry leaders, entrepreneurs, general counsel, and investors. Topics will include how investable healthcare entities leverage intellectual property (IP) to drive growth. Hear from medtech entrepreneurs about their experiences with IP strategy, protection, licensing, and marketing, and how these and other factors have impacted success. Join us for RESI Boston and get to know the team at Husch Blackwell through the panel and their many services for life science entrepreneurs!

Leveraging IP for Growing an Investable MedTech Company
Moderator: Bryan Stewart, Partner, Husch Blackwell

Panelists:

  • Cambre Kelly PhD, Co-Founder & CEO, Reselute; Co-Founder and Vice President, Research & Technology, restor3d
  • Adam T.C. Steege, Founder & President, Trio Labs
  • Timothy J. Skapek, CTO & Co-founder, Protect3d

Hosted by Husch Blackwell, this panel for industry leaders, entrepreneurs, general counsel, and investors explores how investable healthcare entities leverage intellectual property (IP) to drive growth.  Hear from medtech entrepreneurs about their experiences with IP strategy, protection, licensing, and marketing, and how these and other factors have impacted success.

RESI-Boston-2022-Banner - new - 1100px

Launching and Funding Startups with the Chinese University of Hong Kong

11 Aug

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

Life Science Nation (LSN) is collaborating with the Pre-Incubation (PI) Centre at the Chinese University of Hong Kong (CUHK) to deliver an educational workshop on August 23- 24, from 7:00 – 9:00 AM EDT. With a decade of expertise in helping early-stage life science companies fundraise and build strategic relationships, LSN has developed a curriculum delivering several master class workshops to global tech hubs and incubators. Conducted virtually over two days, the workshop will be led by Dennis Ford, CEO of Life Science Nation, and LSN staff members who are experienced in Asia business development. The workshop is catered to new founders and entrepreneurs of early-stage, seed to series B life science companies to navigate their way in launching or progressing their businesses, and covers a wide range of fundamental entrepreneurial concepts:

  • How to launch a startup entity and perform entrepreneurial due diligence
  • Branding and messaging
  • The importance of telling a cogent company story through multiple modalities
  • Ten myths of fundraising

LSN is honored to work with the CUHK PI Centre and their constituents for the first time. The PI Centre is a university-wide initiative at CUHK that stimulates creativity and entrepreneurship, supporting aspiring entrepreneurs to prepare and fine-tune their startups since 2014. The center will host a gathering to facilitate the delivery of the workshop. We look forward to meeting the entrepreneurs at CUHK and providing a constructive experience to advance the success of their businesses.

20220803_LSN_poster_1920x1080_F

Sign up or find more information about the workshop here. Contact Joey Wong, Research Analyst, Hong Kong Business Development at j.wong@lifesciencenation.com with questions

LSN is open to collaborating with tech hubs and incubators around the globe. Find out more about LSN’s education programs here.

RESI-Boston-2022-Banner - new - 1100px

Hot Investor Mandate: USA-Based VC Firm Invests in Life Science Companies From Seed to Series B Rounds, With Strong Interest in AI-Based Technologies

11 Aug

A venture capital firm based in the USA invests in companies in Consumer, Crypto and Life Sciences & Digital Health. For companies in the life sciences, the firm generally invests in Seed and Series A/B rounds, committing between $1-10M in capital.

Within the life sciences, the firm is willing to invest in therapeutics, diagnostics, MedTech, digital health, and R&D services. For therapeutics, the firm will consider therapeutics that are first-in-class, either a novel target or novel therapeutic, but is agnostic to indication. For diagnostics, MedTech, Digital Health, and R&D services, the firm focuses on AI-based technologies. Previous investments include AI-based drug discovery platforms, pathology screening, diagnostic services, and care management platforms.

The firm looks for companies with a strong management team, large market opportunities, and disruptive technology. When investing, the firm is willing to lead or co-invest, and will occasionally take a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm With Offices in North America & Asia Invests in Therapeutics, Diagnostics, and Digital Health in Relation to Cell Therapy and Regenerative Medicine

11 Aug

An early stage venture capital firm is dedicated to building next generation companies in the healthcare sector. The fund is focused on the cell therapy and regenerative medicine sector and will consider opportunities encompassing therapeutics, diagnostics, and those harnessing data to revolutionize the sector. The firm partners with passionate teams that are backed by strong scientific platforms and will primarily invest in preclinical stage assets, contributing $1 – 2M initially. With operations in North America and Asia, the fund take a global approach to building value in their portfolio by linking these two important life science markets and leveraging the respective advantages of each ecosystem.

The firm invests exclusively in technologies relating to cell therapy and regenerative medicine, including precision medicine tools and discovery of new treatment modalities. The company can be in therapeutics, diagnostics or digital health. The firm’s primary areas of interest are oncology, autoimmune disorders, CNS, cardiovascular, renal and liver.

Most of the firm’s investments are in companies either located or looking to enter the Japanese market. The firm can lead or co-invest, and will generally take a board seat when leading.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate VC Arm of Conglomerate Invests in Series A to B Rounds in Therapeutics, Diagnostics, and Digital Health, With Interest in Large Market Opportunities

11 Aug

A corporate venture arm under a large conglomerate invests in a wide range of industries including biotech, ICT, media, food, among others. With regards to life sciences and healthcare, The firm generally invests in Series A to B rounds but has participated in as early as pre-Series A. Typical initial size of investment is over $1M, and is subject to larger amounts depending on the stage of the company. The firm has invested mostly in USA and Korea, but is open to considering global opportunities.

The firm will consider opportunities across therapeutics, diagnostics, digital health. Within these sectors, the firm is most interested in drug discovery and development, diagnostics, digital health, and microbiome. In therapeutics, the firm is open to both pre-clinical and clinical assets & platforms and will consider all different types of modalities (small molecule, antibodies, cell/gene therapy). The firm will consider all indications but is interested in large markets including oncology/immuno-oncology and CNS.

The firm has no specific management team requirements. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Fund of Large Holding Company Seeks Opportunities in Diagnostics and Digital Health Across the Globe

11 Aug

A venture capital fund of a large holding company looks to provide a unique stepping stone for successful companies to broaden their global reach. The firm offers partners deep understanding of relevant audiences and a unique opportunity for truly innovative, trail-blazing consumer-related digital health ventures. The firm is looking to invest in digital therapeutics, POC diagnostics, and other dHealth companies from seed stage and beyond. The firm is interested in companies with well defined, relevant products and solutions, preferably with initial validation or proof-of-concept. The firm invests globally.

Within the digital health and POC diagnostics space, the firm has many areas of interest. These include, but are not limited to, telemedicine, remote monitoring, patient adherence, FemTech and aging, medication dispensing, digital therapeutics, POC and home diagnostics.

The firm has no specific requirements for company and management team, and makes decisions on a case-by-case basis. The firm can lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: